Annals of Oncology
Journal Abbreviation: ANN ONCOL
ISSN: 0923-7534
eISSN: 1569-8041
Publisher: Elsevier
Publications (160)
GMP-compliant human monocyte-derived dendritic cells for cancer vaccination generated by using the Quantum (R) hollow fiber bioreactor system (2019)
Uslu U, Uslu U, Erdmann M, Wiesinger M, Schuler G, Schuler-Thurner B
Conference contribution
Development of adaptive immune effector therapies in solid tumors (2019)
Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, Ruggeri A, et al.
Journal article, Review article
Immunoscore predicts significant differences in time to recurrence in stage I colon cancer patients (2019)
Galon J, Hermitte F, Mlecnik B, Marliot F, Bifulco C, Lugli A, Nagtegaal I, et al.
Conference contribution
Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial (2019)
Kreutzfeldt S, Apostolidis L, Oles M, Horak P, Heilig CE, Heining C, Hutter B, et al.
Conference contribution
Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations (2019)
Turner NC, Laird AD, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, et al.
Conference contribution
Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) (+) ribociclib (RIB) (2019)
Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al.
Conference contribution
KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC) (2019)
Schmid P, Cortes J, Dent R, Pusztai L, Mcarthur HL, Kuemmel S, Bergh J, et al.
Conference contribution
Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study (2019)
Tesch H, Loibl S, Kast K, Jackisch C, Moebus V, Buchen S, Untch M, et al.
Conference contribution
Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC) (2019)
Furlanetto J, Nekljudova V, Schneeweiss A, Thode C, Denkert C, Untch M, Bassy M, et al.
Conference contribution
PRECYCLE Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy (2019)
Degenhardt T, Fasching P, Lueftner D, Mueller V, Thomssen C, Schem C, Witzel I, et al.
Conference contribution